IMVT Immunovant, Inc.

NEUTRAL Impact: 3/10 144
Horizon weeks Filed May 28, 2026 Processed 9d 20h ago SEC 0001950047-26-005198
Form 144 — notice of proposed sale of securities
Latest settled — T+5d
IMVT ▼ -6.58% at T+5d
NEUTRAL call ✗ call lost -6.58% · α vs SPY -4.08% · entry $33.30 → $31.11
Next anchor: T+20d in 11d
Last close $33.62 (close Jun 12) · +0.96% from $33.30 entry
Entry anchored
May 28, 03:59 PM ET
via Databento tick
T+1d
-1.32%
call -1.32% · α -1.58%
$32.86
settled 17d ago
T+5d
-6.58%
call -6.58% · α -4.08%
$31.11
settled 11d ago
T+20d
call — · α —
in 11d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Director Andrew J. Fromkin filed a Form 144 on May 28, 2026, indicating intent to sell up to 221,951 shares of Immunovant common stock (approx. $7.4M at recent prices, ~0.11% of market cap). The shares were acquired primarily via stock option exercises and open-market purchases from 2021-2026, and are being sold through a broker at current market prices. The filing is routine for a director monetizing exercised options and does not suggest material company-specific concerns.

Actionable Insight

Monitor for the execution of this sale (Form 4 filing) over the coming weeks. The dollar amount is modest relative to market cap and liquidity — unlikely to meaningfully pressure the stock. The director is simply monetizing option exercises in a routine manner. No earnings or catalyst event is imminent based on this filing.

Key Facts

  • Form 144 filed May 28, 2026 by director Andrew J. Fromkin
  • Proposed sale of 221,951 shares of common stock
  • Estimated aggregate value ~$7.44M based on ~$33.50 implied price (derived from stated $7.44M / 221,951 shares)
  • Shares acquired via multiple option exercises and RSU vesting events between 2021 and 2026
  • Sale not yet executed — Form 144 is an advance notice of intent to sell
  • Market cap ~$6.7B; proposed sale represents ~0.0033% of shares outstanding
  • Recent insider activity shows 3 prior sells totaling $574K in the last 30 days

Financial Impact

$7.44 million in potential selling proceeds, a minor fraction of $6.7B market cap

dilution

Risk Factors

  • Insider selling could be interpreted negatively by the market, though the amount is very small relative to total shares outstanding
  • The proposed sale has not been executed; market conditions or blackout periods could prevent it

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (24 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005198
Document: 0001950047-26-005198-index.html0001950047-26-005198
Document: 0001950047-26-005198.txt0001950047-26-005198
5 reports for IMVT
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IMVT — sortable, filterable
Type Now
May 28, 2026
17d ago
144
NEUTRAL ★ 3/10
$33.30 $31.11▼ −6.58%▼ −4.08%$33.62 (+0.96%)
May 20, 2026
25d ago
8-K
MIXED ★ 6/10
$35.56 $33.41▼ −6.05%▼ −7.28%$33.62 (−5.46%)
May 20, 2026
25d ago
Press Release
BULLISH ★ 7/10
$35.56 $33.41▼ −6.05%▼ −7.28%$33.62 (−5.46%)
Apr 23, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$28.91 $26.95▼ −6.78%▼ −8.26%$33.62 (+16.29%)
Apr 2, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$24.50 $24.50· 0.00%▼ −3.62%$33.62 (+37.22%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 3h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access